Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 574985, 7 pages
http://dx.doi.org/10.1155/2014/574985
Research Article

Clinical Significance of Survivin Expression in Patients with Urothelial Carcinoma

1Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan
2Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan
3Department of Biomedical Research, Chiayi Christian Hospital, Chiayi 600, Taiwan
4Department of Pathology, Chiayi Christian Hospital, Chiayi 600, Taiwan
5Division of General Surgery, Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan
6Department of Urology, Chiayi Christian Hospital, 539 Chung Hsiao Road, Chiayi 600, Taiwan
7Tainan University of Technology, Tainan City 71002, Taiwan

Received 20 October 2013; Accepted 12 December 2013; Published 5 February 2014

Academic Editor: Marco E. M. Peluso

Copyright © 2014 Hsin-An Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Bureau of Health Promotion, “Department of Health, Taiwan, Republic of China. Cancer registry annual report,” 2012, http://www.hpa.gov.tw/BHPNet/Web/Stat/Statistics.aspx.
  2. Y.-H. Wang, S.-D. Yeh, K.-H. Shen et al., “A significantly joint effect between arsenic and occupational exposures and risk genotypes/diplotypes of CYP2E1, GSTO1 and GSTO2 on risk of urothelial carcinoma,” Toxicology and Applied Pharmacology, vol. 241, no. 1, pp. 111–118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Kakizoe, “Development and progression of urothelial carcinoma,” Cancer Science, vol. 97, no. 9, pp. 821–828, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. W.-J. Kim and S.-C. Bae, “Molecular biomarkers in urothelial bladder cancer,” Cancer Science, vol. 99, no. 4, pp. 646–652, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. S.-K. Chiou, M. K. Jones, and A. S. Tarnawski, “Survivin—an anti-apoptosis protein: its biological roles and implications for cancer and beyond,” Medical Science Monitor, vol. 9, no. 4, pp. PI25–PI29, 2003. View at Google Scholar · View at Scopus
  6. K. Srivastava, A. Srivastava, and B. Mittal, “Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis,” Molecular Biology Reports, vol. 39, no. 2, pp. 1509–1516, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. G. S. Salvesen and C. S. Duckett, “IAP proteins: blocking the road to death's door,” Nature Reviews Molecular Cell Biology, vol. 3, no. 6, pp. 401–410, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Akhtar, L. Gallagher, and S. Rohan, “Survivin: role in diagnosis, prognosis, and treatment of bladder cancer,” Advances in Anatomic Pathology, vol. 13, no. 3, pp. 122–126, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Ambrosini, C. Adida, and D. C. Altieri, “A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma,” Nature Medicine, vol. 3, no. 8, pp. 917–921, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. N. K. Sah, Z. Khan, G. J. Khan, and P. S. Bisen, “Structural, functional and therapeutic biology of survivin,” Cancer Letters, vol. 244, no. 2, pp. 164–171, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Xu, F. Fang, G. Ludewig, G. Jones, and D. Jones, “A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells,” DNA and Cell Biology, vol. 23, no. 9, pp. 527–537, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. Y.-H. Wang, H.-Y. Chiou, C.-T. Lin et al., “Association between survivin gene promoter -31C/G polymorphism and urothelial carcinoma risk in taiwanese population,” Urology, vol. 73, no. 3, pp. 670–674, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. A. Karam, Y. Lotan, R. Ashfaq, A. I. Sagalowsky, and S. F. Shariat, “Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder,” Urology, vol. 70, no. 3, pp. 482–486, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Koike, Y. Sekine, M. Kamiya, H. Nakazato, and K. Suzuki, “Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer,” Urology, vol. 72, no. 6, pp. 1229–1233, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. X. B. Li, S. N. Li, Z. H. Yang et al., “Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population,” DNA Cell Biology, vol. 32, no. 5, pp. 236–242, 2013. View at Google Scholar
  16. L. N. Huang, D. S. Wang, Y. Q. Chen et al., “Expression of survivin and patients survival in non-small cell lung cancer: a meta- analysis of the published studies,” Molecular Biology Reports, vol. 40, no. 2, pp. 917–924, 2013. View at Google Scholar
  17. A. K. Srivastava, P. K. Singh, K. Srivastava et al., “Diagnostic role of survivin in urinary bladder cancer,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 1, pp. 81–85, 2013. View at Google Scholar
  18. J. H. Ku, C. Kwak, H. S. Lee, H. K. Park, E. Lee, and S. E. Lee, “Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder,” Journal of Urology, vol. 171, no. 2, pp. 631–635, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Kitamura, T. Torigoe, Y. Hirohashi et al., “Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma,” Virchows Archives, vol. 462, no. 1, pp. 101–107, 2013. View at Google Scholar
  20. Y. Wu, G. Wang, J. Wei, and X. Wen, “Survivin protein expression positively correlated with proliferative activity of cancer cells in bladder cancer,” Indian Journal of Medical Sciences, vol. 59, no. 6, pp. 235–242, 2005. View at Google Scholar · View at Scopus
  21. W. Yin, N. Chen, Y. Zhang et al., “Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder,” Modern Pathology, vol. 19, no. 11, pp. 1487–1497, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Pasin, D. Y. Josephson, A. P. Mitra et al., “Superfical bladder cancer: an update on etiology, molecular development, classification, and natural history,” Reviews in Urology, vol. 10, no. 1, pp. 31–43, 2008. View at Google Scholar
  23. O. P. Blanc-Brude, M. Mesri, N. R. Wall, J. Plescia, T. Dohi, and D. C. Altieri, “Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis,” Clinical Cancer Research, vol. 9, no. 7, pp. 2683–2692, 2003. View at Google Scholar · View at Scopus
  24. D. C. Altieri, “Survivin in apoptosis control and cell cycle regulation in cancer,” Progress in Cell Cycle Research, vol. 5, pp. 447–452, 2003. View at Google Scholar · View at Scopus
  25. Q. Qin, C. Zhang, H. Zhu et al., “Association between survivin -31G>C polymorphism and cancer risk: meta-analysis of 29 studies,” Journal of Cancer Research and Clinical Oncology, 2013. View at Publisher · View at Google Scholar
  26. X. Wang, L. Huang, Y. Xu et al., “Association between survivin -31G<C promoter polymorphism and cancer risk: a meta-analysis,” European Journal of Human Genetics, vol. 20, pp. 790–795, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Weikert, F. Christoph, M. Schrader, H. Krause, K. Miller, and M. Müller, “Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis,” International Journal of Cancer, vol. 116, no. 1, pp. 100–104, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Wang, D. S. Morris, S. A. Tomlins et al., “Development of a multiplex quantitative PCR signature to predict progression In non-muscle-invasive bladder cancer,” Cancer Research, vol. 69, no. 9, pp. 3810–3818, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. S. F. Shariat, P. I. Karakiewicz, G. Godoy et al., “Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study,” Clinical Cancer Research, vol. 15, no. 22, pp. 7012–7019, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Rödel, T. Sprenger, B. Kaina et al., “Survivin as a prognostic/predictive marker and molecular target in cancer therapy,” Current Medicinal Chemistry, vol. 19, no. 22, pp. 3679–3688, 2012. View at Google Scholar
  31. C. Jeon, M. Kim, C. Kwak, H. H. Kim, and J. H. Ku, “Prognostic role of survivin in bladder cancer: a systematic review and meta-analysis,” PLoS ONE, vol. 8, no. 10, Article ID e76719, 2013. View at Google Scholar
  32. S. Lv, E. Turlova, S. Zhao, H. Kang, M. Han, and H. S. Sun, “Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis,” Tumor Biology, 2013. View at Publisher · View at Google Scholar
  33. M. Lauss, M. Ringnér, and M. Höglund, “Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study,” Clinical Cancer Research, vol. 16, no. 17, pp. 4421–4433, 2010. View at Publisher · View at Google Scholar · View at Scopus